
    
      This was a non-randomized, single institutional, open-label, prospective trial designed to
      evaluate the efficacy and safety of apatinib in combination with camrelizumab for patients
      with biliary tract malignant tumors.

      It is estimated that 20 patients who met the study criteria will be enrolled in PUMCH and
      treated with aptinib and camrelizumab. The investigators will follow up and collect subjects'
      data each month to evaluate the efficacy and safety of treatment, including treatment related
      adverse events, overall survival and time to progression and objective response. Multi-omics
      data analysis will be used to find potential biomarkers of treatment response.
    
  